A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
Clinical trial NCT06126640 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06126640
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-11-20
- Primary completion
- 2030-04-01
- Enrollment
- 1615
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.